Cleveland BioLabs (CBLI) Announces $5.3M Grant
More News related to CBLI
- Cleveland BioLabs (CBLI) Gets Patent for Radiation Protection, Including Protectan CBLB502
- Cleveland BioLabs Granted European Patent for Radiation Protection Drug CBLB502
- Cleveland BioLabs to Present at 12th Annual BIO CEO & Investor Conference
- Cleveland BioLabs Doses First Volunteers in Second Safety Study for CBLB502
- Cleveland BioLabs to Respond to Department of Defense Request for Proposal for Radiation Countermeasure
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
Cleveland BioLabs, Inc. (NASDAQ: CBLI) has been awarded a $5.3 million Grand Opportunities grant under the American Recovery and Reinvestment Act of 2009 from the Office of the Director and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
The grant will fund studies of molecular mechanisms by which Protectan CBLB502 mitigates gastrointestinal (GI) damage from radiation exposure. Cleveland BioLabs will lead a consortium of collaborators on this project, including Roswell Park Cancer Institute, Cleveland Clinic, the University of Illinois at Chicago and Attagene, Inc.
Related Categories
FDAStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
